Caribou Biosciences, Inc.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage biopharmaceutical company developing genome-edited cell therapies for patients with hematologic malignancies. Its CRISPR chRDNA technology uses hybrid RNA-DNA guides to edit cells, including to reduce graft-versus-host disease risk and modify immune… From the company’s description.
Over the twelve months to Sep 30, 2026, Caribou Biosciences, Inc. reported revenue of $9.44M, up 1.6% from a year earlier, and a net loss of $102.47M. Operations used $93.11M in cash. In fiscal 2025, it reported revenue of $11.16M, up 11.7% from fiscal 2024, and a net loss of $148.13M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Caribou Biosciences, Inc. does
In the company’s own words
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage biopharmaceutical company developing genome-edited cell therapies for patients with hematologic malignancies. Its CRISPR chRDNA technology uses hybrid RNA-DNA guides to edit cells, including to reduce graft-versus-host disease risk and modify immune responses. The company’s two clinical-stage programs are off-the-shelf CAR-T therapies made from healthy donor cells: vispa-cel, an anti-CD19 candidate evaluated for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA candidate being evaluated for relapsed or refractory multiple myeloma. Both programs are in Phase 1 clinical trials, and the company is planning a pivotal Phase 3 trial for vispa-cel. Caribou discontinued development of its CB-012 candidate and preclinical research in 2025, prioritizing resources on vispa-cel and CB-011. Founded in 2011, the company also owns patent rights covering its chRDNA genome-editing technology.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BERKELEY, CA
- Fiscal year end
- December
- CIK
- 1619856
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Caribou Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Caribou Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Caribou Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Caribou Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Caribou Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”